a view of how the assemblies of receptors give rise to the functional outcome produced by direct receptorreceptor interactions (FIGURE 2).
Through analyzing the effects of neuropeptides in membrane preparations on the binding characteristics of monoamine receptors in discrete brain regions, the first indications for the existence of intramembrane receptor-receptor interactions between different types of GPCRs were obtained (3, 8, 27, 28) . In vivo functional correlates further demonstrated these receptor-receptor interactions in studies involving the control of blood pressure and the sleep-wakefulness cycle (6, 7, (29) (30) (31) . A logical explanation for these observations was the existence of direct physical interactions between different types of GPCRs, and the molecular process known as heteromerization was proposed to be a mechanism for these receptor-receptor interactions (see Refs. 36, 103) . These findings were in line with the early work by Limbird et al. (62) who showed negative cooperativity among ␤-adrenergic receptors, indicating the existence of homodimers (FIGURE 1). The first direct evidence for the existence of heterodimers came many years later with the demonstration of the GABA B receptor heterodimer and opioid receptor heterodimers formed by different receptor subtypes (see Refs. 56, 66) . Today, a long list of GPCR heteromers exists and continues to expand (for reviews, see e.g., Refs. 5, 16, 23, 26, 33, 34, 38, 42, 69, 71, 81) .
The Terminology of Receptor Heteromerization
In 1982, the Agnati and Fuxe teams proposed the existence of assemblies of multiple (high order) GPCRs of various types within the plasma membrane and coined the term receptor mosaic (RM) for their proposed assembly. These were considered a molecular basis for the engram, by changing the synaptic efficacy, i.e., the synaptic weight (5, 9, 48) . The term receptor mosaic, compared with "high-order oligomers," provides a better vision of its structure since topology (spatial location of each receptor within the RM), in addition to receptor stoichiometry, plays an important functional role. The term receptor mosaic also confers this case with differentially tagged and ␦ opioid receptors, the -␦ heterodimer was also demonstrated (56) . In 2000, coimmunoprecipitation experiments detected heteromeric receptor complexes containing adenosine A 1 and dopamine D 1 receptors; thus one of the first demonstrations of heteromer forming GPCRs with different ligands (43) was obtained along with the agonist-induced somatostatin SSTR5 and dopamine D 2 receptor heteromers identified during the same year (85) .
The coimmunoprecipitation of membrane receptors has the drawback that it requires their solubilization using detergent treatment. Technological advances were made, and now, by means of biophysical methods based on light resonance energy transfer [bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET)] it became possible to obtain improved indications for heterodimers/RMs in living cells. With BRET and FRET techniques, the A 2A /D 2 heterodimer/receptor mosaic could be strongly indicated in cell lines (18, 57) after its demonstration with coimmunoprecipitation (35, 52) . These techniques devoted for the specific investigation of GPCR oligomerization are in continuous expansion. Accordingly, novel technical approaches including sequential BRET-FRET (19) and combined BRET-BiFC (bimolecular fluorescence complementation) (39, 50) have been developed. Interestingly, these two approaches, based on biophysical resonance energy transfer, allow the detection of three or more interacting receptors. To date, using these novel techniques, it has become possible to safely distinguish heterodimers vs. receptor mosaics of different GPCRs (17, 68, 70, 87) .
Identification of Receptor Mosaics
Using atomic force microscopy, Fotiadis and colleagues (25) obtained indications that rhodopsin exists as highorder arrays of dimers that display a paracrystalline arrangement in the native disc membrane of the retina. In addition, this method, used in combination with immunogold labeling, indicated that receptor mosaics formed by D 2L receptors may display a ring-like structure (11) . Based on combined bioluminescence/fluorescence energy transfer and complementation techniques, it has recently been possible to demonstrate that four D 2 receptors or more form a receptor mosaic at physiological expression levels (50) . The concept of direct receptor-receptor interactions between different receptors at the level of the plasma membrane and thus probably involving heteromerization was originally based on the ability of peptides to modulate the binding characteristics of monoamine receptors in membrane preparations from different brain regions (8, 28) . Homomerization of receptors was first indicated from the work of Lefkowitz and colleagues demonstrating negative cooperativity in <beta-adrenergic receptors (62) . The receptor-receptor interactions can sometimes be mediated by adapter proteins transferring the conformational change from one receptor to the other as indicated at right. FIGURE 2. Theoretical functional outcomes from homodimers and heterodimers of GPCRs and from a trimeric receptor mosaic of different types of GPCRs (high-order heteromers)
The GABA B1 subunits of GABA B heterodimers were close to each other, but this was not true for the GABA B2 subunits. Thus the GABA B heterodimers appear to constitutively organize into dimers of dimers in a specific way. Through the formation of such a receptor mosaic, the G protein-coupling efficacy appeared to be reduced compared with the GABA B heterodimer, thus offering a new way to modulate the G-proteincoupling (67) . In contrast, the mGluR1 did not assemble into receptor mosaics but exclusively formed mGluR1 homodimers.
Based on this recent work, it seems clear that different types of GPCR receptor mosaics may be formed depending on the "Lego-like" properties of the individual participating receptors and their spatial location or topology (the assembly of individual tesserae of the receptor mosaic). RMs could be highly polymorphic structures with a limited number of molecules linked to create a large number of different spatial arrangements. As a consequence, a distinct number of topologies, and thus morphologies, can be developed within the receptor mosaic from a limited number of receptor elements (see Ref. 1) .
Based on a Boolean network modeling of the receptor mosaic, it becomes more clear that the integrative activity of a receptor mosaic on activation can be significantly changed by modifying the arrangement of the receptor-receptor interactions between the participating receptors without changing their number (11) . A general definition of RM has been proposed by Agnati and Fuxe in 2002 (2) that considers the likely localization of the assembly of receptors within a molecular network of membrane and receptor-associated proteins (Horizontal Molecular Network: HMN) linked to the intracellular signaling cascades (Vertical Molecular Network: VMN) operating as effectors of the system together with the plasma membrane ligand and voltage-gated ion channels to modulate gene expression and excitability. The definition is mainly stated as follows: "A RM is an assemblage of more than two receptors, which can bind and decode signals (transmitters, allosteric modulators, etc.) to produce an integrated input to one or more than one intracellular cascade via allosteric receptor-receptor interactions. "
Future work will improve this definition of receptor mosaics now that their existence has been demonstrated by the use of novel technologies. It should be considered that the plasma membrane microenvironment of the receptor mosaic would have an important modulatory role of its integrative activity through influencing the conformational panorama of the participating receptors and thus the receptor-receptor interactions taking place. Of special interest are the lipid rafts in the plasma membrane, which is a strictly ordered lipid phase rich in sphingolipids and cholesterol. (78) .
One of the novel techniques mentioned above, sequential BRET-FRET (SRET), was developed specifically for the identification of trimeric RMs (19) . Through a combination of BRET and FRET, trimeric receptor mosaics could be identified. This method seems to be a crucial technique for finally identifying receptor mosaics, which represent essential integrative nodes in the plasma membrane (11, 34) that were postulated to exist by Agnati and colleagues as early as 1982 (9) . Using the SRET technique, it became possible to demonstrate the existence of a CB 1 At about the same time, another exciting paper was published (67) with a novel methodology using timeresolved FRET with snap-tag technology to quantitatively assess protein-protein interactions at the surface of living cells. The exciting finding was made that the GABA B receptors could form dimers of heterodimers. trafficking as well as cytoskeletal organization (10, 21) . Lipid rafts are divided into two main structural types, namely caveolae and planar lipid raft, with the former containing caveolin proteins. Interestingly, neurons express caveolin proteins, but these cells are devoid of caveolae (84) . Instead, neurons contain planar lipid rafts where the receptor mosaics and heterodimers may be differentially modulated versus the plasma membrane regions outside these lipid rafts. The neuronal plasma membrane also contains flotillin, a protein analogous to caveolin (see Ref. 54) , which is believed to modulate the receptor-receptor interactions and thus the integrative activity and function of the heterodimers and the receptor mosaics. It therefore seems likely that the emergent activity of the receptor mosaics and heterodimers can be substantially modulated by their expression in lipid rafts.
REVIEWS

The Receptor Interface Among GPCR Receptor Heterodimers and Receptor Mosaics
Both intracellular and extracellular domains are involved in the interfaces between GPCRs oligomers. In the case of the GABA B receptor, an obligate heterodimer, the interaction interface is predominantly formed by the transmembrane domains and coiledcoil interactions in the COOH-terminal tails of the GABA B1 and GABA B2 receptor subtypes (see Ref. 65) . As for mGluR5 and mGluR1 receptor homodimers, the interface for each respective homodimer was instead found to be disulfide bridges (77, 86) located within the large NH 2 -terminal extracellular domains. Data from the crystal structure of the ligand binding regions of the mGluR1 indicate that glutamate binds to the crevice (venus flytrap domain; VFT) between the two binding domains (see Ref. 55) . Glutamate binding results in a rearrangement of the VFT, which, via an allosteric mechanism, is transferred to the heptahelical effector domain that leads to a transduction of the glutamate-mediated receptor conformational change to the G protein (88) . Also, the sweet and umami taste receptors, also belonging to class C GPCRs, have been shown to be functional only when forming heterodimers (61, 75, 76, 102) . The functional sweet taste receptor is formed from T1R2 and T1R3 and the umami receptor from T1R1 and T1R3. Thus the dimer is probably required in this family of GPCRs for the transfer of the conformational change from the extracellular agonist-binding pocket to the heptahelical transmembrane domains (79) .
It has been found that it is more difficult to identify the transmembrane (TM) domains that interact among various heteromers. The first studies in 1996 by Hebert and colleagues (51) on the ␤ 2 -adrenergic receptors indicated that TM6 was involved since peptides from the TM6 domain blocked their dimerization. The first transmembrane interaction to be demonstrated among the GPCRs was the one between the two TM4 domains in the interface of the D 2 homodimer (49) , and today most TM domains have been implicated in the dimeric interactions among class A GPCRs (see Refs. 72, 89) .
In the beginning, only contacts between TM helices (contact dimers) were considered, but based on the functional rescue studies performed by Maggio and colleagues in 1993 on chimeric (mutant) muscarinicadrenergic receptors, Reynolds, Gouldson, and colleagues (Ref. 47 ; see also Ref. 89) introduced the model of domain swapping at the TM5 and TM6 interface based on molecular modeling and bioinformatics. It has also been possible to reconstitute the binding site of two deficient mutants of the type 1 angiotensin II receptor (73) , and domain swapping has been demonstrated in the histamine H1 receptor but only from functionally impaired receptors (14) .
The pioneering work of Amina Woods (96) gave evidence of a fundamental role for electrostatic epitopeepitope interactions in the formation of the interfaces between receptor proteins leading to the assemblage of heterodimers and receptor mosaics. As an example, electrostatic interactions between an arginine-rich, highly conserved epitope (basic motif ), found in the underlies direct inhibition of receptor activation (92) . Interestingly, in this proposed heterodimer-based mechanism, the agonist-mediated conformational changes of one receptor propagate to the other and cause the second receptor's rapid inactivation. These trans-inhibition phenomena are based on cross-conformational changes within a named heterodimer that may constitute a fast way of precluding overstimulation of signaling pathways (92) . These findings are in line with early findings on antagonistic neuropeptide Y (NPY) Y 1 receptor-␣ 2 receptor interactions at the recognition level and in central cardiovascular regulation (32, (98) (99) (100) .
Generally speaking, the allosteric phenomena involve either cooperative interactions among homomers and heterodimers of isoreceptors or non-cooperative interactions in other types of heterodimers with regard to modulation between the orthosteric centers (5, 11, 34, 38, 48, 71) . These allosteric mechanisms cause antagonistic or facilitatory effects on the binding properties, G-protein coupling and trafficking of the receptors, and is the major molecular mechanism that gives rise to the functional outcome of the heterodimer.
Recently FIGURE 4)  (20) . This was demonstrated using mass spectrometry and was confirmed with biochemical pull-down assays. The arginine-phosphate electrostatic interaction possesses a "covalent like" stability (53) . The work also highlights the importance of phosphorylationdephosphorylation events in the modulation of such electrostatic attraction at receptor interfaces. Phosphorylation of the acidic motif by casein kinase on one receptor makes it available for interaction with the basic motif on the other. On the other hand, phosphorylation of serine and/or threonine residues downstream from the basic motif by protein kinase A or C slows down the attraction between the epitopes. The arginine-phosphate electrostatic interaction most likely represents a general mechanism in protein-protein interactions (97) .
The Allosteric Regulation of GPCR Heterodimers and Receptor Mosaics
Heterodimers
It is likely that allosteric mechanisms play a crucial role for interactions within heterodimers and receptor mosaics of GPCRs. The molecular basis involves allosteric mechanisms with neurotransmitter-induced conformational changes in one receptor that propagate via the oligomer interfaces to the adjacent receptors. Indeed, the existence of a trans-conformational switching mechanism has recently been demonstrated between ␣ 2A -adrenergic and -opioid receptors that REVIEWS 
Receptor mosaic
It is becoming clear that allosteric regulation takes place not only in monomeric and multimeric proteins but also in allosteric networks in the PDZ domain, dimers (see above), and macromolecular assemblies (see Ref. 46 ) like receptor mosaics. Long-range communication via allostery may exist in protein structures and assemblies, and allosteric regulation may also exist in the absence of conformational changes by being dynamically driven. A major factor for the assembly of macromolecular complexes is cooperativity (95) . Thus cooperativity is also a thermodynamic term used to characterize conformational transitions in macromolecular complexes. Thus it is likely that cooperativity drives the assembly of the receptor mosaics representing multicomponent complexes of receptors involving both endogenous (receptor proteins) and exogenous (neurotransmitters) cooperativity (38) . Cooperativity in 30S ribosome assembly and in Notch transcription factor complexes has in fact been described (95) . Cooperativity appears to be a crucial mechanism for organizing interdependence of macromolecules in assemblies, making biological complexity possible (94); also not only allosteric but also configurational cooperativity may exist in receptor mosaics.
The Physiology of Receptor Heterodimers/Receptor Mosaics
Effects on receptor recognition and signaling
A 2A -D 2 heteromerization. The major physiological role of this heterodimer/receptor mosaic located in the striato-pallidal GABA neurons can be a direct A 2A -D 2 receptor-receptor interaction by which A 2A activation can reduce the affinity of the D 2 agonist binding site, especially the high-affinity component, via allosteric antagonistic mechanisms contributing to a strong reduction in D 2 G-protein-coupling and D 2 signaling over adenylate cyclase and phospholipase C (FIGURE 6A) (24, 36, 37) . Thus endogenous adenosine can inhibit D 2 signaling, which contributes to increasing activity in the striato-pallidal GABA neurons and thus to motor inhibition and Parkinsonian-like effects. These studies led to the development of A 2A antagonists for treatment of Parkinson's disease (37, 38) . (64) . Thus the physiological role of the D 1 -D 3 heteromer, mainly located in the direct striato-nigral/pallidal GABA pathway, may be to allow the activated D 3 receptor to enhance D 1 receptor recognition and signaling via allosteric mechanisms leading to positive cooperativity in the D 1 receptor since DA is the agonist for both receptors. This function will be of relevance for D 1 -mediated motor functions in the direct pathway, and when exaggerated by prolonged L-DOPA treatment, and may also contribute to development of dyskinesias in Parkinson's disease (64) . Thus D 3 antagonists may be useful in its treatment.
Effects on G-protein selection
The D 1 -D 2 receptor heterodimer/receptor mosaic is an example of how the formation of a heteromer can switch the G-protein coupling of participating receptors to other G proteins (58, 83) . Thus, upon coactivation of D 1 and D 2 receptors in this heterodimer/receptor mosaic, a selective G q/11 activation occurs, producing increases in PLC activity and a rapid rise in intracellular calcium levels without influencing adenylate cyclase activity regulated by G s and G i proteins. In this way, the PLC can become activated, leading to intracellular calcium release and increased levels of calcium/calmodulindependent protein kinase II␣ contributing to synaptic plasticity (82) . This represents an interesting example of how the formation of receptor heterodimer/receptor mosaics increases the diversity of signaling pathways that can be used by receptor subtypes, in this case DA receptor subtypes and thus their functional repertoire in the brain. Its dysfunction may contribute to neuropsychiatric disease.
5-HT 2A -mGluR2 heteromerization. Recently, an exciting discovery was made by Gonzalez-Maeso, Milligan, Sealfon, and colleagues, which involved 5-HT 2A receptor forming a receptor mosaic with mGluR2 via transmembrane helices 4 and 5 of mGluR2 in the brain cortex (44) . This receptor mosaic may be the major target for hallucinogenic drugs since it allows the hallucinogenic 5-HT 2A agonists to produce conformational changes in these 5-HT 2A receptors in such a way that they become able to activate not only G q/11 but also the G i/o protein and its signaling pathways, necessary for their hallucinogenic effects (45) . This is another example of how unique conformational changes may develop in a receptor of a receptor mosaic altering its pattern of G-protein coupling in response to special agonists as a result of allosteric mechanisms operating via the receptor interfaces. Activation of mGluR2 328 PHYSIOLOGY • Volume 23 • December 2008 • www.physiologyonline.org been obtained through the demonstration that this receptor assembly regulates NMDA-mediated excitation and firing in ventral striato-pallidal GABA neurons (FIGURE 6B) (13). D 2 receptor-mediated suppression of NMDA-induced depolarized plateau potential involving an inhibition of spiking is reversed by A 2A agonists. By loading the neurons with either SAOEpS or the SAOES peptides, which are known to bind to the arginine rich motif of the NH 2 -terminal part of the IC loop of the D 2 receptor, the A 2A agonist could no longer counteract the D 2 -mediated suppression of the NMDA-induced depolarized plateau potential via the Cav 1.3a L-type calcium channel current through D 2 -PLC signaling with calcineurin activation followed by dephosphorylation of these calcium channels. Therefore, spiking activity remained blocked (13). antagonizes the 5-HT 2A -mediated hallucinogenic signaling in this receptor mosaic via allosteric interactions at the recognition and G-protein coupling, giving mGluR2 agonists an antischizophrenic potential.
REVIEWS
Effects on receptor trafficking and ␤ ␤-arrestin
-opioid receptor (MOR1)-substance P receptor (NK1) heteromerization. Constitutive NK1-MOR1 heteromerization markedly changed the internalization and resensitization profile of the two receptors without altering their recognition and signaling (80) . The major finding was that substance P receptor activation enhanced cross-phosphorylation and cointernalization of MOR1. When coexpressed alone, however, the class A MOR1 receptor preferentially binds the ␤-arrestin 2 but only transiently interacts with ␤-arrestin, which directs it to clathrin-coated pits. Thus the complex rapidly dissociates with ␤-arrestin recycling to the plasma membrane, which is true also for MOR1, which rapidly recycles and resensitizes. In contrast, class B receptors like the NK1 receptors have no preference for ␤-arrestin 1 and 2 and form stable complexes with ␤-arrestin, which leads to slow recycling and resensitization. As a consequence of its physical interaction with the NK1 receptor in the heterodimer leading to cointernalization along the class B internalization pathway, MOR1 will develop slow recycling and delayed resensitization after NK1 receptor activation with substance P, resulting in MOR1 desensitization. In view of the coexpression of MOR1 and NK1 in spinal cord neurons, this receptor-receptor interaction will be of relevance for nociceptive mechanisms and lead to a reduction in the anti-nociceptive actions of morphine.
It should also be considered that MOR1 activation caused cross-phosphorylation of the NK1 receptor. Therefore, homologous crossphosphorylation of the receptor heterodimer may contribute to its cointernalization with ␤-arrestin in endosomes by increasing its binding to the receptor also involving conformational changes induced in the NK1 via the receptor interface in the heterodimer. In view of the discovery of Lefkowitz and his colleagues that ␤-arrestins can act not only in desensitization but also as transducers of receptor signaling via signaling complexes with ERK and receptor kinases (15, 59, 60) , the study on NK1-MOR1 heteromerization also indicates that receptorreceptor interactions in heteromers/receptor mosaics can have a role in switching between G-proteindependent and ␤-arrestin-dependent signaling at heptamembrane spanning receptors. This may also inter alia involve conformational changes in the receptor-G protein interface of the heterodimer, favoring an increased binding of ␤-arrestin. Furthermore, activated ERK remains associated with stable class B receptor-␤-arrestin complexes, which, in turn, limits nuclear translocation of ERK and its effects on gene expression, which is a major difference versus G-protein-dependent signaling (90) . A 1 -P2Y 1 receptor heteromerization. Very interesting changes in the A 1 receptor pharmacology have been discovered by Nakata and his team in A 1 -P2Y 1 receptor heteromers (74, 101) . This heteromerization results in a conformational change in the A 1 binding pocket leading to the appearance of an A 1 receptor with P2Y 1 -like agonistic pharmacology. In fact, a P2Y 1 agonist binds to the A 1 receptor and produces an inhibition of AC that is blocked by an A 1 antagonist. Therefore, this A 1 receptor-mediated ATP response can be one of the mechanisms that might account for the ATP-induced inhibition of transmitter release since it is co-released from nerve terminal networks.
opioid and ␦ ␦ opioid receptor heteromerization. It has been observed that a series of highly selective synthetic agonists for each opioid receptor had a diminished potency and also a different pharmacological profile for this heterodimer, whereas Leuenkephalin and endomorphin-1 showed increased affinities (41) . Thus novel pharmacological properties had developed. On the basis of the existence of -␦ opioid receptor heterodimers with ␦ ligands enhancing the efficacy of agonists, bivalent compounds have inter alia been developed built up of a agonist linked to a ␦ antagonist, which shows special analgesic properties (22) . The pharmacology of the receptor mosaics has in fact led to the introduction of bivalent ligands that can become useful in treatment of disease, especially in relation to reduction of the development of tolerance to morphine.
Concluding Remarks
The field of receptor heterodimers and receptor mosaics involving direct receptor-receptor interactions continues to expand. A new principle in molecular medicine has emerged since these interactions not only modulate receptor recognition but also G-protein selection, signaling, and receptor trafficking. The pharmacology of the different receptors within heterodimers/RM also becomes markedly altered via such mechanisms with respect to their pharmacology as monomers or homomers. Novel pharmacological properties continue to emerge as heterodimers and receptor mosaics are further evaluated, which will lead to the development of novel neuropsychopharmacology. The GPCR field has now moved from single acting units, or receptors acting as monomers, to more complex and regulated integrative signaling centers as heterodimers and receptor mosaics.
